GAD treatment and insulin secretion in recent-onset type 1 diabetes

Cited by (520)

Items 201–300 of 520

1. Tolerogenic Nanoparticles to Treat Islet Autoimmunity
   Tobias Neef, Stephen D. Miller · 2017 · Current Diabetes Reports
2. The potential of incretin-based therapies in type 1 diabetes
   Chen S. Suen, Paul Burn · 2011 · Drug Discovery Today
3. Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes
   Kimber M. Simmons, Peter A. Gottlieb, Aaron W. Michels · 2016 · Current Diabetes Reports
4. Prevention of type 1 diabetes
   Sally Thrower, P. J. Bingley · 2011 · British Medical Bulletin
5. Immune Intervention in Type I Diabetes Mellitus
   Johnny Ludvigsson · 2013 · InTech eBooks
6. 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Immune therapies of type 1 diabetes: new opportunities based on the hygiene hypothesis
   Lucienne Chatenoud, Sylvaine You, Hikaru Okada, Chantal Kuhn, B Michaud, Jean‐François Bach · 2010 · Clinical & Experimental Immunology
7. Therapeutic Effects of BCG Vaccination on Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
   Yu‐Chen Chang, Chien‐Ju Lin, Yu-Hsuan Hsiao, Yu-Han Chang, Shu‐Jung Liu, Hsin‐Yin Hsu · 2020 · Journal of Diabetes Research
8. Tolerance-inducing medicines in autoimmunity: rheumatology and beyond
   James A Stanway, John Dudley Isaacs · 2020 · The Lancet Rheumatology
9. C-peptide in diabetes diagnosis and therapy
   Johnny Ludvigsson · 2012 · Frontiers in Bioscience-Elite
10. Autoantigen based vaccines for type 1 diabetes.
    Dequina Nicholas, Oludare Odumosu, William H. R. Langridge · 2011 · PubMed
11. Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity
    Naomi Richardson, David Cameron Wraith · 2021 · Immunotherapy Advances
12. Distinctions between islet neogenesis and β‐cell replication: Implications for reversal of Type 1 and 2 diabetes
    Claresa S. Levetan · 2010 · Journal of Diabetes
13. Non-antigenic and antigenic interventions in type 1 diabetes
    Anna KE Rydén, Johnna D. Wesley, Ken T. Coppieters, Matthias G. von Herrath · 2013 · Human Vaccines & Immunotherapeutics
14. Frequency and severity of ketoacidosis at onset of autoimmune type 1 diabetes over the past decade in children referred to a tertiary paediatric care centre: potential impact of a national programme highlighted
    Ahmet Uçar, Nurçin Saka, Firdevs Baş, Mine Şükür, Şükran Poyrazoğlu, Feyza Darendelıler, Rüveyde Bundak · 2013 · Journal of Pediatric Endocrinology and Metabolism
15. Prevention of type 1 diabetes: today and tomorrow
    Simona Cernea, Minodora Dobreanu, Itamar Raz · 2010 · Diabetes/Metabolism Research and Reviews
16. Analysis of antigen specific T cells in diabetes – Lessons from pre-clinical studies and early clinical trials
    Balasubramanian Krishnamurthy, Claudia Selck, Jonathan Chee, Gaurang Jhala, Thomas W. H. Kay · 2016 · Journal of Autoimmunity
17. Peptide Immunotherapies in Type 1 Diabetes: Lessons from Animal Models
    Alessandra Fierabracci · 2011 · Current Medicinal Chemistry
18. Stem cell treatment for type 1 diabetes
    Ming Li, S. Ikehara · 2014 · Front. Cell Dev. Biol.
19. The impact of insulin administration during the mixed meal tolerance test
    Rachel E.J. Besser, Angus G. Jones, Timothy James McDonald, Beverley M. Shields, Bridget Knight, Andrew Tym Hattersley · 2012 · Diabetic Medicine
20. Comparison of the prevalence of islet autoantibodies according to age and disease duration in patients with type 1 diabetes mellitus
    Young Hwa Kong, Min Sun Kim, Dae‐Yeol Lee · 2013 · Annals of Pediatric Endocrinology & Metabolism
21. Autoimmune Diabetes: An Overview of Experimental Models and Novel Therapeutics
    Sylvaine You, Lucienne Chatenoud · 2015 · Methods in molecular biology
22. Emerging treatments for the prevention of type 1 diabetes
    Philip Raskin, Alok Mohan · 2010 · Expert Opinion on Emerging Drugs
23. Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase
    Frans Gorus, Bart Keymeulen, Pieter In 'T Veld, DANIEL G. PIPELEERS · 2013 · Expert Review of Clinical Immunology
24. Combined Etanercept, GAD‐alum and vitamin D treatment: an open pilot trial to preserve beta cell function in recent onset type 1 diabetes
    Johnny Ludvigsson, Indusmita Routray, Tore Vigård, Ragnar Hanås, Björn Rathsman, Annelie Carlsson, Stefan Särnblad, Anna‐Karin Albin, Carl‐Göran Arvidsson, Ulf Samuelsson et al. · 2021 · Diabetes/Metabolism Research and Reviews
25. Antigen-specific immunotherapy to restore antigen-specific tolerance in Type 1 diabetes and Graves’ disease
    Aakansha Zala, Ranjeny Thomas · 2022 · Clinical & Experimental Immunology
26. Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus
    Binbin He, Xia Li, Haibo Yu, Zhiguang Zhou · 2015 · Journal of Diabetes
27. Effect of gamma aminobutyric acid (GABA) or GABA with glutamic acid decarboxylase (GAD) on the progression of type 1 diabetes mellitus in children: Trial design and methodology
    Heather M. Choat, Alexandra Martin, Gail J. Mick, Katie E. Heath, Hubert Ming Tse, Gerald G. McGwin, Kenneth L. McCormick · 2019 · Contemporary Clinical Trials
28. Challenges in developing endpoints for type 1 diabetes intervention studies
    Simona Cernea, Itamar Raz, Kevan C. Herold, Boaz Hirshberg, Bart O. Roep, Desmond Schatz, G. Alexander Fleming, Paolo Pozzilli, Randie R. Little, Nanette Cathrin Schloot et al. · 2009 · Diabetes/Metabolism Research and Reviews
29. Characteristics ofin-vitrophenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals
    Mikael Chéramy, Christiane S. Hampe, Johnny Ludvigsson, Rosaura Casas · 2012 · Clinical & Experimental Immunology
30. The clinical potential of low-level C-peptide secretion
    Johnny Ludvigsson · 2016 · Expert Review of Molecular Diagnostics
31. Gastrointestinal Tract and Endocrine System
    Carsten Keil, Elmar Jäckel, Michael Peter Manns, Oliver P. Bachmann · 2016 · Springer eBooks
32. Vaccination against type 1 diabetes
    Helena Elding Larsson, Åke Lernmark · 2011 · Journal of Internal Medicine
33. Changes in GAD65Ab-Specific Antiidiotypic Antibody Levels Correlate with Changes in C-Peptide Levels and Progression to Islet Cell Autoimmunity
    Eva Örtqvist, Barbara Brooks‐Worrell, Kristian Francis Lynch, Jared R. Radtke, Lynn M. Bekris, Ingrid Skelton Kockum, C.–D. Agardh, Corrado Cilio, ÅsaLinda Lethagen, B. Persson et al. · 2010 · The Journal of Clinical Endocrinology & Metabolism
34. Protease-resistant human GAD-derived altered peptide ligands decrease TNF-α and IL-17 production in peripheral blood cells from patients with type 1 diabetes mellitus
    Bernhard Otto Boehm, Silke Rosinger, Guido Sauer, Burkhard J. Manfras, David Palesch, S Schiekofer, Hubert Kalbacher, Timo Burster · 2009 · Molecular Immunology
35. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
    Rosaura Casas, Fabrícia Dietrich, Sara Puente-Marín, Hugo Barcenilla, Beatriz Tavira, Jeannette Wahlberg, Peter Achenbach, Johnny Ludvigsson · 2022 · Acta Diabetologica
36. Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes
    Mark C. Johnson, Bo Wang, Roland Tisch · 2011 · Human Vaccines
37. Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis
    Kongye Lu, Benli Su, Xiuxiang Meng · 2018 · Journal of Diabetes Research
38. Prevention of Type 1 Diabetes: Past Experiences and Future Opportunities
    Przemysław Beik, Martyna Ciesielska, Maria Kucza, Alicja Kurczewska, Joanna Kuźmińska, Bartosz Maćkowiak, Elżbieta Niechciał · 2020 · Journal of Clinical Medicine
39. Efforts to Prevent and Halt Autoimmune Beta Cell Destruction
    Michael J. Haller, Mark A. Atkinson, Desmond Schatz · 2010 · Endocrinology and Metabolism Clinics of North America
40. Trials in the Prevention of Type 1 Diabetes: Current and Future
    Diane K. Wherrett · 2014 · Canadian Journal of Diabetes
41. Altered immune profile from pre-diabetes to manifestation of type 1 diabetes
    Anna Rydén, Maria Faresjö · 2013 · Diabetes Research and Clinical Practice
42. Persistence is the Twin Sister of Excellence
    Greenbaum, Carla, Atkinson, Mark A. · 2011 · Diabetes
43. C‐peptide an adequate endpoint in type 1 diabetes
    Johnny Ludvigsson · 2009 · Diabetes/Metabolism Research and Reviews
44. Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we?
    Linda Avesani, Luisa Bortesi, Luca Santi, Alberto Falorni, Mario Pezzotti · 2010 · Expert Review of Vaccines
45. Physical Activity, Blood Glucose and C-Peptide in Healthy School-Children, a Longitudinal Study
    Karina Huus, Linda Åkerman, Anders Raustorp, Johnny Ludvigsson · 2016 · PLoS ONE
46. Revisiting multiple models of progression of β‐cell loss of function in type 1 diabetes: Significance for prevention and cure
    Xia Li, Jin Cheng, Zhiguang Zhou · 2016 · Journal of Diabetes
47. Immune response differs between intralymphatic or subcutaneous administration of GAD‐alum in individuals with recent onset type 1 diabetes
    Fabrícia Dietrich, Hugo Barcenilla, Beatriz Tavira, Jeanette Wahlberg, Peter Achenbach, Johnny Ludvigsson, Rosaura Casas · 2021 · Diabetes/Metabolism Research and Reviews
48. Proficiency Testing of Human Leukocyte Antigen-DR and Human Leukocyte Antigen-DQ Genetic Risk Assessment for Type 1 Diabetes Using Dried Blood Spots
    Paul Dantonio, Nancy Meredith-Molloy, William Hagopian, Jin‐Xiong She, Beena Akolkar, Suzanne Kehoe Cordovado, Miyono M. Hendrix, L. Omar Henderson, W. Harry Hannon, Robert F. Vogt · 2010 · Journal of Diabetes Science and Technology
49. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients
    Mikael Pihl, Hugo Barcenilla, Stina Axelsson, Mikael Chéramy, Linda Åkerman, Ingela Johansson, Johnny Ludvigsson, Rosaura Casas · 2017 · Clinical Immunology
50. DiaPep277® and immune intervention for treatment of type 1 diabetes
    Nanette Cathrin Schloot, Irun R. Cohen · 2013 · Clinical Immunology
51. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes
    Dario Tuccinardi, Elvira Fioriti, Silvia Manfrini, Eugenio D'Amico, Paolo Pozzilli · 2011 · Expert Opinion on Biological Therapy
52. Current and future efforts toward the prevention of type 1 diabetes
    Laura M. Jacobsen, Desmond Schatz · 2016 · Pediatric Diabetes
53. Combined Vitamin D, Ibuprofen and Glutamic Acid decarboxylase-alum Treatment in Recent Onset Type I Diabetes: Lessons from the DIABGAD Randomized Pilot Trial
    Johnny Ludvigsson, Indusmita Routray, Sri Ramulu Elluru, Per Leanderson, Helena Elding Larsson, Björn Rathsman, Ragnar Hanås, Annelie Carlsson, Torben Ek, Ulf Samuelsson et al. · 2020 · Future Science OA
54. Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
    Hugo Barcenilla, Mikael Pihl, Jeanette Wahlberg, Johnny Ludvigsson, Rosaura Casas · 2022 · Frontiers in Immunology
55. Self-Antigens Targeted by Regulatory T Cells in Type 1 Diabetes
    Angela M. Mitchell, Aaron W. Michels · 2022 · International Journal of Molecular Sciences
56. GAD-Alum Immunotherapy in Type 1 Diabetes Mellitus
    Alba E. Morales, Kathryn M. Thrailkill · 2011 · Immunotherapy
57. Immunotherapies for prevention and treatment of type 1 diabetes
    Rebecca Jeun · 2025 · Immunotherapy
58. Regulatory T cell phenotype and function 4 years after GAD–alum treatment in children with type 1 diabetes
    M. Pihl, Linda Åkerman, Stina Axelsson, Mikael Chéramy, M Hjorth, Roberto Mallone, Johnny Ludvigsson, Rosaura Casas · 2013 · Clinical & Experimental Immunology
59. Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
    Toshio Kahara, Toshinari Takamura, Toshiki Otoda, Kazuhide Ishikura, Eiki Matsushita · 2009 · Internal Medicine
60. In vitro(re)programming of human bone marrow stromal cells toward insulin-producing phenotypes
    Catarina Limbert, Jochen Seufert · 2009 · Pediatric Diabetes
61. The Effect of Immunosuppressive Adjuvant Kynurenine on Type 1 Diabetes Vaccine
    Jing Sun, Jiandong Shi, Jianfang Li, Meini Wu, Yanhan Li, Sengquan Jia, Chunli Ma, Xinyi Wang, Zhiyuan Li, Ningzhu Hu et al. · 2021 · Frontiers in Immunology
62. Immunotherapies in Diabetes Mellitus Type 1
    Smita Gupta · 2012 · Medical Clinics of North America
63. Post-translational modifications contribute to neoepitopes in Type-1 diabetes: Challenges for inducing antigen-specific tolerance
    Sivasangari Balakrishnan, Prabhakaran Kumar, Bellur S. Prabhakar · 2020 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
64. Cloning, expression, purification and characterization of the cholera toxin B subunit and triple glutamic acid decarboxylase epitopes fusion protein in Escherichia coli
    Zhaohui Gong, Xiang-E. Long, Lin Pan, Yanping Le, Qiong Liu, Shaomin Wang, Junming Guo, Bingxiu Xiao, Mi Zhou, Disen Mei · 2009 · Protein Expression and Purification
65. Combination Therapies for Type 1 Diabetes: Why Not Now?
    Matthias von Herrath · 2010 · Immunotherapy
66. The latest pharmacotherapy options for type 1 diabetes
    Johnny Ludvigsson · 2013 · Expert Opinion on Pharmacotherapy
67. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus
    Shannon A. Miller, Erin St. Onge · 2011 · Expert Opinion on Biological Therapy
68. Does immune-tolerance treatment with Alum-formulated GAD65 protect insulin-production in the pancreatic islet β cells?
    Helena Elding Larsson, Åke Lernmark · 2011 · Human Vaccines
69. Review: The importance of residual endogenous beta-cell preservation in type 1 diabetes
    Mohammad Alhadj Ali, Colin Mark Dayan · 2009 · The British Journal of Diabetes
70. Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation
    Darius Schneider, Alexandra Kretowicz, Matthias G. von Herrath · 2012 · Diabetes Obesity and Metabolism
71. Decreased GAD65‐specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD‐alum
    Stina Axelsson, M. Hjorth, Johnny Ludvigsson, Rosaura Casas · 2012 · Diabetic Medicine
72. Antigen-based vs. systemic immunomodulation in type 1 diabetes
    Sofie Robert, Hannelie Korf, Conny A. Gysemans, Chantal Mathieu · 2013 · Islets
73. Management of type 1 diabetes mellitus
    Michael Conall Dennedy, Seán F. Dinneen · 2010 · Medicine
74. Immune mechanisms of intraocular inflammation
    Lauren P. Schewitz‐Bowers, Richard Lee, Andrew D. Dick · 2010 · Expert Review of Ophthalmology
75. From pumps to prevention: recent advances in the treatment of type 1 diabetes
    Jennifer L. Sherr, Eda Cengiz, William V. Tamborlane · 2009 · Drug Discovery Today
76. Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments
    Liudmila Kosheleva, Daniil Koshelev, Francisco Alejandro Lagunas‐Rangel, Shmuel Levit, Alexander Rabinovitch, Helgi B. Schiöth · 2025 · Pharmacological Reviews
77. National Institutes of Health Center for Human Immunology Conference, September 2009
    Robert Burton Nussenblatt, Bibiana Bielekova, Richard W. Childs, Alan M. Krensky, Warren Strober, Giorgio Trinchieri · 2010 · Annals of the New York Academy of Sciences
78. Teaching the immune system “self” respect and tolerance
    Lucienne Chatenoud · 2014 · Science
79. Autoantibodies to N-terminally Truncated GAD65(96-585): HLA Associations and Predictive Value for Type 1 Diabetes
    Petra M Pöllänen, Taina Härkönen, Jorma Ilonen, Jorma Toppari, Riitta Veijola, Heli Siljander, Mikael Knip · 2021 · The Journal of Clinical Endocrinology & Metabolism
80. Immunotherapies currently in development for the treatment of type 1 diabetes
    Ian Davis, Jacqueline Randell, Stephen N. Davis · 2015 · Expert Opinion on Investigational Drugs
81. The Year in Immune Intervention for Type 1 Diabetes
    Jay S. Skyler · 2013 · Diabetes Technology & Therapeutics
82. The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients
    Jin Liu, Lingling Bian, Ji Li, Yang Chen, Heng Chen, Yong Gu, Bingqin Ma, Wei Gu, Xinyu Xu, Yun Shi et al. · 2016 · Science China Life Sciences
83. Strategies to prevent type 1 diabetes
    Sally Thrower, P. J. Bingley · 2009 · Diabetes Obesity and Metabolism
84. Biophysical Properties of Self-Assembled Immune Signals Impact Signal Processing and the Nature of Regulatory Immune Function
    Eugene Froimchuk, Robert S. Oakes, Senta M. Kapnick, Alexis A. Yanes, Christopher M. Jewell · 2021 · Nano Letters
85. Partial Clinical Remission Reduces Lipid-Based Cardiovascular Risk in Adult Patients With Type 1 Diabetes
    Benjamin Udoka Nwosu, Sadichchha Parajuli, Krish Khatri, Gabrielle Jasmin, Layana Al‐Halbouni, Austin F. Lee · 2021 · Frontiers in Endocrinology
86. Particle-Based therapies for antigen specific treatment of type 1 diabetes
    Nicole Rose Lukesh, Denzel D. Middleton, Eric M. Bachelder, Kristy M. Ainslie · 2022 · International Journal of Pharmaceutics
87. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype
    Sara Puente-Marín, Fabrícia Dietrich, Peter Achenbach, Hugo Barcenilla, Johnny Ludvigsson, Rosaura Casas · 2023 · Frontiers in Immunology
88. Monitoring immunomodulation strategies in type 1 diabetes
    Balasubramanian Krishnamurthy, Matthew Lacorcia, Thomas W. H. Kay, Helen E. Thomas, Stuart I. Mannering · 2023 · Frontiers in Immunology
89. Therapie des Typ-2-Diabetes
    Rüdiger Landgraf, Monika Kellerer, Jens Aberle, Eva-Maria Fach, Baptist Gallwitz, Andreas Hamann, Hans‐Georg Joost, Harald Klein, Dirk Müller‐Wieland, Michael Albrecht Nauck et al. · 2018 · Diabetologie und Stoffwechsel
90. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response
    Beatriz Tavira, Mikael Chéramy, Stina Axelsson, Linda Åkerman, Johnny Ludvigsson, Rosaura Casas · 2017 · Diabetologia
91. Antigen-Specific Therapy Against Type 1 Diabetes: Mechanisms and Perspectives
    Xiaoxiao Wan, Habib Zaghouani · 2014 · Immunotherapy
92. Type 1 (Insulin-Dependent) Diabetes Mellitus
    Ahmed J. Delli, Åke Lernmark · 2015 · Elsevier eBooks
93. Identification of Candidate Tolerogenic CD8+T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model
    Cailin Yu, Jeremy Carlos Burns, William H. Robinson, Paul J. Utz, Peggy Pui-Kay Ho, Lawrence Steinman, Alan B. Frey · 2016 · Journal of Diabetes Research
94. Natural Food Pigments
    Benjamin Kofi Simpson, Soottawat Benjakul, Sappasith Klomklao · 2012
95. Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic diseases
    Benjamin Cai, Ranjeny Thomas · 2024 · Best Practice & Research Clinical Rheumatology
96. Recent Advances in the Prevention of Hypoglycemia in Type 1 Diabetes
    Jaime Realsen, H. Peter Chase · 2011 · Diabetes Technology & Therapeutics
97. Prevention of Type 1 Diabetes
    Diane K. Wherrett, Denis Daneman · 2011 · Pediatric Clinics of North America
98. GAD65: a prospective vaccine for treating Type 1 diabetes?
    Johnny Ludvigsson · 2017 · Expert Opinion on Biological Therapy
99. Linking autoantigen properties to mechanisms of immunity
    J. Daniel Griffin, Jimmy Y. Song, Joshua O. Sestak, Brandon J. DeKosky, Cory J. Berkland · 2020 · Advanced Drug Delivery Reviews
100. Epigenetic Changes Induced by Maternal Factors during Fetal Life: Implication for Type 1 Diabetes
     Ilaria Barchetta, Jeanette Arvastsson, Luís Sarmiento, Corrado Cilio · 2021 · Genes